Pre-made Codrituzumab benchmark antibody ( Whole mAb, anti-GPC3 therapeutic antibody, Anti-DGSX/GTR2-2/MXR7/OCI-5/SDYS/SGB/SGBS/SGBS1 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Codrituzumab biosimilar, Whole mAb, Anti-GPC3 Antibody: Anti-DGSX/GTR2-2/MXR7/OCI-5/SDYS/SGB/SGBS/SGBS1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Codrituzumab is a humanized monoclonal antibody targeted at glypican-3 (GPC3), which is a member of the glypican family. This drug is developed by Chugai Pharmaceutical in combination with Roche and has been investigated in the treatment of liver cancer.
| Products Name (INN Index) | Pre-Made Codrituzumab biosimilar, Whole mAb, Anti-GPC3 Antibody: Anti-DGSX/GTR2-2/MXR7/OCI-5/SDYS/SGB/SGBS/SGBS1 therapeutic antibody |
|---|---|
| INN Name | Codrituzumab |
| Target | GPC3 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2013 |
| Year Recommended | 2014 |
| Companies | Perseus Proteomics,Chugai Pharmaceutical,Roche |
| Conditions Approved | NA |
| Conditions Active | Liver cancer |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | GPC3 |
| Package |
